Three-Stage Design for Demonstration

Interim Analysis for Futility Using Bayesian Predictive Probability

Dung-Tsa Chen

30 April 2019

===

Summary of Interim Analysis for Futility

Futility evaluation is implemented in 2 interim analyses with 15, 15 patients in stage 1, 2, respectively, and 20 patients in the last stage, for a total of 50 patients. With an unfavorable rate set at 30% (null hypothesis) and posterior probability of 0.95 as the threshold, a total of at least 21 of the 50 patients must have response to be able to claim treatment efficacy. Given a 20% cutoff of the predictive probability (i.e. chance to stop the trial in the interim analyses) the stopping rule (Table 1) will be: the trial will be stopped if there are 4, and 10 or less patients with response in the 1st to 2nd interim analysis, respectively.

Performance of the design (Figure 2 and Table 3) shows that if the true rate of response is 30%, the chance to reach at least a total of 21 patients with response at end of the study is 4% (Type I error), however the probability to stop the trial early is 77%. If true rate of response is indeed 50%, then the chance to reach at least 21 patients with response at end of the study is 85% (power), and the corresponding probability to stop the treatment early is 9%.

Details

A Bayesian approach for futility analysis is used to calculate posterior probability and predictive probability for the rate of response with a non-informative beta prior, beta(1,1), using the analytical form. We consider a 30% rate or lower of response as ineffective for the treatment. Thus, we expect the treatment arm is promising if the posterior probability of the rate (response) greater than 30% is higher than 0.95 (i.e., prob(rate of response>30% |data)>0.95)).

With a total 50 patients in treatment arm, the number of patients with response needs to be 21 or more in order to meet the criteria. Therefore, we use the number of 21 patients to guide the predictive probability. Specifically, given the number of patients with response, s, in the first 15 patients, we calculate predictive probability of $21 - s$ or more patients with response in the future remaining 35 patients, i.e., $\sum_{i=21-s}^{35} \binom{35}{i} \frac{beta(1+s+i,1+(15-s)+(35-i))}{beta(1+s,1+(15-s))}$. Calculation of predictive probability is based on beta binominal distribution for the number of patients with response in the future remaining 35 patients given a beta distribution for the rate of response, $beta(1 + s, 1 + 15 - s)$. For example, if there are 4 patients with response in the first 15 patients, the predictive probability of 17 or more patients with response in the future remaining 35 patients would be $\sum_{i=17}^{35} \binom{35}{i} \frac{beta(1+4+i,1+(15-4)+(35-i))}{beta(1+4,1+(15-4))} = 0.099$.

The predictive probability is also calculated for each of the remaining interim analyses to evaluate the chance of 21-s or more patients with response in the future remaining patients given s patients with response in the current stage of interim analysis. Figure 1 and Table 2 lists predictive probability for all scenarios of number of patients with response in each interim analysis and the associated largest number of patients with response needed in the future remaining patients to have at least a total of 21 patients with response.

We consider that a 20% cutoff of the predictive probability will give unlikely chance to have 21 patients or more with response at the end of study. Thus with this cutoff, the stopping rule (Table 1) will be: the trial will be stopped if there are 4, and 10 or less patients with response in the 1st to 2nd interim analysis,

respectively. Performance of this stopping rule (Figure 2 and Table 3) shows that if the true rate of response is 30%, the chance to reach at least a total of 21 patients with response at end of the study is 4% (Type I error), however the probability of early termination (PET) is 77%. When the true rate of response is 50%, then the chance to reach at least 21 patients with response at end of the study is 85% (power), and the corresponding probability to stop the treatment early is 9%. Figure 3 shows the probability of stopping at each interim analysis.

Sensitivity analysis (Table 4-7 and Figure 4-7) evaluates four parameters for their impact on performance (PET, type I error, and power): cutoff for the predictive probability, threshold for posterior probability of response rate, sample size, and beta prior distribtuion of the response rate. Evaluation is conducted for each parameter when the values of other parameters are fixed. When the cutoff of the predictive probability for the stopping rule is 0.01-0.3, the range is 0.45-0.88 for PET, 0.03-0.05 for type I error, and 0.78-0.9 for power (Table 4 and Figure 4). When the threshold for posterior probability is 0.8-0.99, the range is 0.62-0.93 for PET, 0.01-0.18 for type I error, and 0.67-0.96 for power (Table 5 and Figure 5). When the sample size of each stage is in the magnitude from decrease by -5 to increase by 5, the range is 0.74-0.84 for PET, 0.03-0.06 for type I error, and 0.77-0.92 for power (Table 6 and Figure 6). When the beta prior varies from non-informative prior to the one with a response rate at the null or alternative hypothesis and a series of standard deviation (SD), the range is 0.29-0.99 for PET, 0-0.31 for type I error, and 0.25-0.99 for power (Table 7 and Figure 7).

Table 1: Stopping Boundary for Futility

Stage of interim analysis	1	2	Final
Sample size up to the current stage	15	30	50
Sample size at each stage	15	15	20
Stopping boundary	4	10	20

Table 2: Bayesian Predictive Probability for Stopping Rule

number of patients with response in the 1st interim analysis	minimum number of patients with response needed in the future remaining patients	predictive probability
0	21	0.000
1	20	0.000
2	19	0.005
3	18	0.027
4	17	0.099
5	16	0.254
6	15	0.481
7	14	0.713
8	13	0.879
9	12	0.963
10	11	0.992
11	10	0.999
12	9	1.000
13	8	1.000
14	7	1.000
15	6	1.000

number of patients with response in the 2nd interim analysis	minimum number of patients with response needed in the future remaining patients	predictive probability
1	20	0.000
2	19	0.000
3	18	0.000
4	17	0.000
5	16	0.000
6	15	0.000
7	14	0.001
8	13	0.006
9	12	0.029
10	11	0.094
11	10	0.230
12	9	0.437
13	8	0.664
14	7	0.844
15	6	0.946
16	5	0.986
17	4	0.998
18	3	1.000
19	2	1.000
20	1	1.000

Table 3: Performance (Probability of Early Termination, Type I error, and Power)

true rate	overall probability of early stopping the trial	probability to have at least 21 patients with response
0.05	1.000	0.000
0.10	1.000	0.000
0.15	0.998	0.000
0.20	0.979	0.000
0.25	0.912	0.005
0.30	0.769	0.041
0.35	0.566	0.163
0.40	0.357	0.393
0.45	0.190	0.659
0.50	0.086	0.855
0.55	0.033	0.952
0.60	0.011	0.987

Table 4: Sensitivity Analysis: Predictive Probability

Cutoff of predictive probability	PET	typeI	power
0.01	0.45	0.05	0.90
0.05	0.62	0.05	0.89
0.10	0.77	0.04	0.85
0.15	0.77	0.04	0.85
0.20	0.77	0.04	0.85
0.25	0.85	0.04	0.83
0.30	0.88	0.03	0.78

Table 5: Sensitivity Analysis: Posterior Probability

threshold of posterior probability	PET	typeI	power
0.80	0.62	0.18	0.96
0.81	0.62	0.18	0.96
0.82	0.62	0.18	0.96
0.83	0.62	0.18	0.96
0.84	0.68	0.11	0.91
0.85	0.68	0.11	0.91
0.86	0.68	0.11	0.91
0.87	0.68	0.11	0.91
0.88	0.68	0.11	0.91
0.89	0.68	0.11	0.91
0.90	0.77	0.07	0.88
0.91	0.77	0.07	0.88
0.92	0.77	0.07	0.88
0.93	0.77	0.07	0.88
0.94	0.77	0.07	0.88
0.95	0.77	0.04	0.85
0.96	0.77	0.04	0.85
0.97	0.88	0.02	0.74
0.98	0.88	0.02	0.74
0.99	0.93	0.01	0.67

Table 6: Sensitivity Analysis: Sample Size

n1	n2	n3	PET	typeI	power
10	10	15	0.78	0.06	0.78
11	11	16	0.74	0.06	0.79
12	12	17	0.76	0.04	0.78
13	13	18	0.83	0.03	0.77
14	14	19	0.84	0.04	0.81
15	15	20	0.77	0.04	0.85
16	16	21	0.83	0.04	0.83
17	17	22	0.84	0.04	0.86
18	18	23	0.78	0.04	0.90
19	19	24	0.80	0.05	0.92
20	20	25	0.84	0.04	0.90

Table 7: Sensitivity Analysis: Beta Prior Distribution

	beta.a	beta.b	PET	typeI	power
0/0	0.00	0.00	0.77	0.04	0.85
0/1	0.00	1.00	0.88	0.03	0.78
1/0	1.00	0.00	0.77	0.07	0.88
1/1	1.00	1.00	0.77	0.04	0.85
0.3 (SD=0.05)	24.90	58.10	0.99	0.00	0.25
0.3 (SD=0.1)	6.00	14.00	0.95	0.01	0.62
0.3 (SD=0.2)	1.27	2.97	0.88	0.03	0.78
0.3 (SD=0.3)	0.40	0.93	0.77	0.04	0.85
0.5 (SD=0.1)	12.00	12.00	0.29	0.31	0.99
0.5 (SD=0.2)	2.62	2.62	0.77	0.07	0.88
0.5 (SD=0.3)	0.89	0.89	0.77	0.04	0.85

Figure 1: Bayesian Predictive Probability for Stopping Rule

1st Interim Analysis of for Futility
minimum number of patients with response needed in the future remaining 35 patients

2nd Interim Analysis of for Futility
minimum number of patients with response needed in the future remaining 20 patients

number of patients with response in the 2nd interim analysis with 30 patients

Figure 2: Performance (Probability of Early Termination (PET), Type I error, and Power)

Overall probability of early stopping the trial (PET)

Probability of at least 21 patients with response

Figure 3: Probability of Early Stopping by Each Interim Analysis

Interim Analysis: 2
Probability of early stopping the trial

Figure 4: Sensitivity Analysis: Predictive Probability

Figure 5: Sensitivity Analysis: Posterior Probability

**Figure 6: Sensitivity Analysis: Sample Size**

Figure 7: Sensitivity Analysis: Beta Prior Distribution

13

References

Chen et al, Application of Bayesian predictive probability for interim analysis in single-arm early phase II trial. Submitted

Lee JJ and Liu DD. A predictive probability design for phase II cancer clinical trials. Clinical trials. 2008; 5: 93-106.